BM0021

BMY-14802

≥97% (HPLC)

• Synonym(e): α-(4-Fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol, (±)-BMY 14802, BMS 181100, BMY-014802, BMY14802
• Empirische Formel (Hill-System): C₁₈H₂₂F₂N₄O
• CAS-Nummer: 105565-56-8
• Molekulargewicht: 348.39
• MDL-Nummer: MFCD00899512
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 329774364

Eigenschaften

• Assay: ≥97% (HPLC)
• Form: powder
• Farbe: white to beige
• Löslichkeit: DMSO: 5 mg/mL, clear (warmed)
• Lagertemp.: room temp
• SMILES String: FC1=CC=C(C(O)CCCN2CCN(C3=NC=C(F)C=N3)CC2)C=C1
• InChI: 1S/C18H22F2N4O/c19-15-5-3-14(4-6-15)17(25)2-1-7-23-8-10-24(11-9-23)18-21-12-16(20)13-22-18/h3-6,12-13,17,25H,1-2,7-11H2
• InChIKey: ZXUYYZPJUGQHLQ-UHFFFAOYSA-N

Beschreibung

Biochem./physiol. Wirkung

BMY-14802 is a potent and selective sigma-1 (σ1) receptor antagonist with an IC₅₀ value of approximately 100 nM. BMY-14802 shows low affinity at serotonin (5-HT) 1A and adrenergic σ1 receptors and minimal activity at dopamine receptors. BMY-14802 has exhibited antipsychotic activity in rodent models and anti-dyskinetic effects against L-DOPA with preservation of antiparkinsonian efficacy.

Leistungsmerkmale und Vorteile

BMY-14802 is available through a partnership with Bristol-Myers Squibb (BMS). To learn more and view other BMS compounds, visit sigma.com/BMS.

Rechtliche Hinweise

Sold for research purposes only under agreement from BMS.

Sicherheitshinweise

• Piktogramme: GHS07
• Signalwort: Warning
• H-Sätze: H315,H319,H335
• P-Sätze: P305 + P351 + P338
• Gefahreneinstufungen: Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• Zielorgane: Respiratory system
• Lagerklassenschlüssel: 13 - Non Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable